Capital International Investors Nu Cana PLC Transaction History

Capital International Investors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.74 - $3.27 $2.2 Million - $9.74 Million	-2,977,153 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.95 - $2.85 $2.81 Million - $4.1 Million	-1,440,000 Reduced 32.6%	2,977,153 $7.68 Million
Q3 2020 Nov 13, 2020	BUY	$4.57 - $6.48 $4.78 Million - $6.77 Million	1,045,000 Added 30.99%	4,417,153 $22.8 Million
Q1 2020 May 15, 2020	BUY	$4.02 - $9.05 $2.98 Million - $6.72 Million	742,476 Added 28.23%	3,372,153 $19.7 Million
Q4 2019 Feb 18, 2020	BUY	$5.55 - $8.48 $3.25 Million - $4.97 Million	585,689 Added 28.65%	2,629,677 $16 Million
Q3 2019 Nov 14, 2019	BUY	$6.95 - $10.71 $4.2 Million - $6.47 Million	603,988 Added 41.94%	2,043,988 $14.8 Million
Q3 2018 Nov 14, 2018	BUY	$20.12 - $26.86 $29 Million - $38.7 Million	1,440,000 New	1,440,000 $35.9 Million

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $64.2M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.